Nina Capital

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

Sonar is a healthcare company focusing on the proactive identification and intervention of mental health challenges in youth.

Connective Health offers a digital health platform that provides clinical-grade summaries of patients' electronic health records (EHR), along with real-time insights. This system consolidates patient history, findings, medications, diagnoses, and behavioral care information to assist healthcare providers in saving time and delivering accurate treatment.

Selfii is a healthcare technology company that operates a data collection platform. It aggregates and structures patient-consented healthcare data from various sources like electronic health records and patient-generated data. This data is then transformed into a comprehensive medical knowledge graph, enabling researchers and healthcare professionals to accelerate clinical research, AI development, and app creation.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Sober Sidekick is a mobile app and social networking platform that supports sobriety and addiction recovery. It connects users in a judgment-free community, providing a sobriety tracker and access to recovery resources to help individuals quit alcohol and drugs and stay on track through peer support and social engagement.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

Quantivly, Inc., established in 2019 and headquartered in Somerville, Massachusetts, specializes in developing artificial intelligence-based solutions tailored for the field of radiology. The company focuses on enhancing data liquidity and providing analytical tools that enable radiology providers to make informed decisions, thereby increasing access to medical imaging services. Quantivly's platform is designed to manage and analyze MRI imaging workflows by cleaning and harmonizing scanner data, resulting in a vendor-neutral and comprehensive source of operational knowledge. This innovative approach supports radiology departments and imaging centers in utilizing data analytics to improve decision-making, facilitate new research initiatives, and enhance the overall patient experience in healthcare.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

QuantHealth is a company focused on enhancing drug development through artificial intelligence-based software. This software is designed to conduct patient-centric simulations that accelerate and de-risk the drug development process. By integrating diverse data points from the clinical and drug development landscape, QuantHealth predicts patient responses to both existing and new therapies. This capability allows pharmaceutical and biotechnology firms to explore various scenarios within their clinical trials, optimizing trial designs and improving the likelihood of successful outcomes. Ultimately, QuantHealth's solutions facilitate the discovery of new clinical opportunities and strategies for optimizing drug development.

Lillian is building a nationwide network of health facilities in Germany.

Basys.ai streamlines healthcare administration by automating prior authorization and utilization management processes for health plans using an AI-based platform. This proprietary system digitizes payer policies via machine learning, reducing implementation timelines significantly.

Alfie Health is a virtual obesity management clinic that focuses on sustainable weight loss through a combination of precision medicine and behavioral change. Utilizing proprietary AI clinical decision support technology, Alfie Health continuously analyzes patient data, including medication history and metabolic information, to tailor individualized weight management plans. The platform also offers regular telehealth visits, ensuring ongoing medical supervision and support for users. Additionally, patients are connected with certified health coaches who assist in determining the most effective medication combinations to achieve their weight loss goals. This innovative approach aims to provide comprehensive care from the convenience of patients' homes.

Sober Sidekick is a mobile app and social networking platform that supports sobriety and addiction recovery. It connects users in a judgment-free community, providing a sobriety tracker and access to recovery resources to help individuals quit alcohol and drugs and stay on track through peer support and social engagement.

Adora Health is a digital health company focused on supporting women's health, particularly during menopause. It has developed an application that utilizes natural language processing and artificial intelligence to provide personalized health management solutions. The platform offers a range of tools, including telehealth services, tailored advice, and lifestyle recommendations, all aimed at helping women navigate their health and well-being during this significant life stage. By integrating technology with women's health needs, Adora Health empowers users to make informed decisions regarding their nutrition and overall wellness.

Hypercare is a healthcare coordination platform designed to enhance clinical communication and collaboration among healthcare providers. Recognizing the challenges posed by traditional communication methods, such as switchboards and pagers, the platform aims to improve patient-centered care by enabling seamless connections across various healthcare settings, including hospitals, long-term care facilities, community care organizations, and family practices. Hypercare addresses the inefficiencies of existing communication channels by minimizing interruptions and allowing healthcare professionals to communicate and locate one another quickly and effectively. This innovative approach mitigates the risks associated with using non-secure messaging applications, thereby protecting patient privacy and reducing medico-legal liabilities for healthcare providers and institutions.

CalmiGo is a company that develops a portable, drug-free medical device aimed at providing immediate relief from emotional and mental distress. The device utilizes advanced technology to help users manage moments of anxiety, stress, and distress by regulating their breathing patterns and stimulating their senses. This innovative solution is designed to be accessible to individuals of all ages and varying technical abilities, allowing them to address anxiety-related issues effectively, regardless of their location. By focusing on a natural approach, CalmiGo offers a convenient and immediate alternative for those seeking relief without the use of medication.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Chiefy is a healthcare company based in New York that focuses on enhancing surgical safety and efficiency through its innovative perioperative team collaboration platform. Founded in 2020 by Maya Ber Lerner and Assaf Ziv, Chiefy aims to promote zero waste and zero harm in surgical procedures. The platform facilitates asynchronous virtual huddles, allowing surgeons, anesthesiologists, nurses, and other healthcare stakeholders to align on case plans before surgery. Additionally, it captures lessons, notes, and feedback post-procedure, fostering a culture of continuous improvement. By integrating quality and communication best practices into daily operations, Chiefy enables healthcare teams to collaborate more effectively, ultimately enhancing patient care and streamlining administrative tasks throughout the surgical journey.

hi.health is a health‑insurance technology company that streamlines the claims process for private insurers. It offers co‑branded debit cards that members can use worldwide at health‑related facilities, eliminating out‑of‑pocket expenses and reducing claim friction. The platform aggregates digital services, invoices, and prescriptions, providing insurers with real‑time data, structured cost visibility, and fraud controls. By integrating payment and insurance functions, hi.health helps insurers improve member experience, cut operational and fraudulent costs, and encourage cost‑conscious behavior through reward and cashback programs.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. The company specializes in enhancing endoscopic procedures through advanced technologies such as artificial intelligence, deep learning, and computer vision. Its flagship product is the Automatic Polyp Detection System (APDS), which aids physicians during colonoscopy by automatically identifying suspicious polyp locations in real-time or in offline mode on pre-recorded videos. This innovation is designed to improve the accuracy of polyp detection, thereby reducing the miss-rate associated with colonoscopies, which can lead to interval cancer. Given the high volume of colonoscopy procedures performed annually, Magentiq Eye's solutions aim to enhance diagnostic effectiveness, ultimately contributing to better patient outcomes and significant healthcare cost savings. The APDS can be integrated with existing colonoscopy systems or offered as a service to clinics and hospitals, positioning Magentiq Eye as a key player in the medical device industry focused on improving endoscopic practices.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, specializing in the development of a machine platform for the large-scale, industrial manufacturing of personalized cell therapies aimed at treating cancer. The company employs advanced semiconductor technology and microfluidic processing to facilitate real-time process control and manipulation at the cellular level. This innovative approach enables a fully automated and modular manufacturing system, enhancing the efficiency and safety of cell therapies while making them more cost-effective for patients. Based in Hinterstoder, Austria, Sarcura is poised to transform manufacturing paradigms in the field of patient-specific cancer treatment.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

IMA Contigo, developed by BERDAC Smart Services S.L., is an innovative tablet dispenser designed to assist individuals in managing their medication schedules. Based in Barcelona, Spain, the device alerts users when it is time to take their medication, effectively reducing the risk of forgetfulness and errors in medication intake. By prioritizing user-friendliness, IMA aims to enhance patient adherence to prescribed treatments and ultimately improve health outcomes.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.

Healee is a health tech company that provides a configurable telehealth platform for digital health innovators to deploy virtual care models. Its platform enables a fully branded patient experience and supports end-to-end clinical workflows, including telehealth visits, digital check-in and scheduling, while consolidating tools to reduce digital fatigue and align with electronic health records, e-prescribing and billing systems. The system also supports patient-doctor communication, health status tracking and sharing, and virtual consultations to help healthcare providers deliver efficient care and improve patient access.

Formulator is a mental healthcare platform designed to streamline the case formulation process for mental health professionals and their clients. By providing a structured tool, the platform enables individuals to articulate their situations and goals, facilitating effective communication with their clinicians from the outset. This approach enhances the productivity and accessibility of mental health care, allowing healthcare providers to address patients' core issues more efficiently. Formulator aims to simplify the initial steps of therapy, ultimately supporting better outcomes for clients and clinicians alike.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

QuantHealth is a company focused on enhancing drug development through artificial intelligence-based software. This software is designed to conduct patient-centric simulations that accelerate and de-risk the drug development process. By integrating diverse data points from the clinical and drug development landscape, QuantHealth predicts patient responses to both existing and new therapies. This capability allows pharmaceutical and biotechnology firms to explore various scenarios within their clinical trials, optimizing trial designs and improving the likelihood of successful outcomes. Ultimately, QuantHealth's solutions facilitate the discovery of new clinical opportunities and strategies for optimizing drug development.

MySecondEar is an e-commerce company specializing in hearing aids and accessories. It offers a digital platform that facilitates the entire hearing aid process, from consultation and initial fitting to fine adjustments, all conducted online. The company provides customers with a diverse selection of hearing aid options, enhancing their ability to engage with the world of sound. Additionally, MySecondEar employs hearing care professionals who are readily available to address any customer inquiries through an online inquiry form on their website, ensuring a comprehensive support system for users.

Taika3D Oy specializes in 3D design automation, particularly for the orthotics and prosthetics industry. The company's platform leverages 3D scanning and intelligent machine vision to rapidly capture images and generate 3D models, facilitating the creation of custom designs with remarkable speed and consistency. This innovation addresses the challenge of producing complex custom designs efficiently, significantly reducing design time by over 95%. Additionally, Taika3D’s technology enhances production scalability, minimizes errors and returns, and supports real-time design reviews. By streamlining the design process, Taika3D empowers laboratories to harness the advantages of 3D printing for mass customization, while also preserving the expertise of their teams. The applications of their technology extend beyond orthotics and prosthetics, encompassing various sectors that require precise and modular product creation.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

Quantivly, Inc., established in 2019 and headquartered in Somerville, Massachusetts, specializes in developing artificial intelligence-based solutions tailored for the field of radiology. The company focuses on enhancing data liquidity and providing analytical tools that enable radiology providers to make informed decisions, thereby increasing access to medical imaging services. Quantivly's platform is designed to manage and analyze MRI imaging workflows by cleaning and harmonizing scanner data, resulting in a vendor-neutral and comprehensive source of operational knowledge. This innovative approach supports radiology departments and imaging centers in utilizing data analytics to improve decision-making, facilitate new research initiatives, and enhance the overall patient experience in healthcare.

Neuroute is an AI-driven platform designed to streamline clinical trial patient recruitment. It employs artificial intelligence to create targeted recruitment strategies and campaigns, connecting healthcare professionals with patients more efficiently.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

hi.health is a health‑insurance technology company that streamlines the claims process for private insurers. It offers co‑branded debit cards that members can use worldwide at health‑related facilities, eliminating out‑of‑pocket expenses and reducing claim friction. The platform aggregates digital services, invoices, and prescriptions, providing insurers with real‑time data, structured cost visibility, and fraud controls. By integrating payment and insurance functions, hi.health helps insurers improve member experience, cut operational and fraudulent costs, and encourage cost‑conscious behavior through reward and cashback programs.

MedAll is a training platform designed for healthcare professionals and students, functioning as a virtual medical school. It provides healthcare organizations with the ability to deliver, store, and share their training courses, conferences, and teaching sessions in one centralized location, facilitating international access to educational resources. The platform also includes features for organizing training feedback, managing portfolios, and generating certificates, abstracts, and schedules. By streamlining these processes into a single paperless platform, MedAll aims to enhance the quality and accessibility of healthcare training globally.

Alfie Health is a virtual obesity management clinic that focuses on sustainable weight loss through a combination of precision medicine and behavioral change. Utilizing proprietary AI clinical decision support technology, Alfie Health continuously analyzes patient data, including medication history and metabolic information, to tailor individualized weight management plans. The platform also offers regular telehealth visits, ensuring ongoing medical supervision and support for users. Additionally, patients are connected with certified health coaches who assist in determining the most effective medication combinations to achieve their weight loss goals. This innovative approach aims to provide comprehensive care from the convenience of patients' homes.

Cardiomatics is a developer of advanced cloud-based artificial intelligence software specifically designed for the analysis of electrocardiogram (ECG) data. The company's medical-grade system utilizes proprietary algorithms that have been validated against both arrhythmia databases and clinical data, ensuring reliable and high-quality outcomes. By providing an easy-to-read reporting format, Cardiomatics enhances the diagnostic capabilities of healthcare providers and streamlines their workflows. The company collaborates with physicians, manufacturers, and ECG device providers on a global scale, positioning itself as a significant player in the digital health technology sector.

Lena Health operates a text-based virtual assistant for patients, enabling clinics and value-based care providers to streamline care tasks. The platform uses conversational AI with optional human support to help patients schedule appointments, coordinate care, navigate services, and support medication adherence, with a focus on individuals with chronic conditions. Through SMS-based interactions, Lena Health reduces call queues and offers a convenient self-service channel that supports providers in delivering value-based care and improving health outcomes.

The Lowdown is an online platform based in London that helps women choose, access and use contraception and reproductive healthcare. Founded in 2019, it combines user-generated content with medical guidance to provide information, reviews and prescriptions where available. The platform emphasizes a community-first approach, allowing users to share experiences with different contraceptive methods, compare symptoms and side effects, and obtain real-world advice to support informed decisions about hormonal and non-hormonal options.

Promptly Health is a health data analytics company that specializes in collecting, integrating, and analyzing data related to healthcare outcomes. The company has developed proprietary technology aimed at enhancing patient engagement and facilitating real-world data collection and outcomes analytics. By discovering digital biomarkers associated with critical symptoms, adverse effects, and treatment outcomes, Promptly Health provides valuable insights into patient care. Its technology not only anticipates patient experiences before starting treatments but also allows for tracking progress throughout the treatment process. This comprehensive approach offers validated information on clinical conditions, symptoms, recovery, and healthy living strategies, ultimately enabling patients to monitor the outcomes of their medical treatments effectively. Through collaborations with innovative healthcare organizations, Promptly Health aims to improve healthcare quality while reducing costs for numerous patients.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

MoveUP is a company focused on developing and commercializing digital therapeutics solutions designed to enhance healthcare delivery. Its innovative platform features a closed-loop system that ensures high compliance and improved outcomes for patients. By continuously collecting data, the platform personalizes treatment plans, significantly enhancing patient satisfaction. MoveUP's initial product targets orthopedic patients recovering from joint surgery, providing a user-friendly medical-grade mobile application that supports faster recovery. The company holds CE medical device and ISO 13485 certifications, underscoring its commitment to quality and regulatory standards in the healthcare sector.

contextflow develops AI-based solutions for radiology image search and analysis. Its flagship product is a 3D image-based search engine that delivers summary of clinical findings, similar reference cases, and relevant diagnosis support for radiologists. The company partners with healthcare institutions and pharmaceutical companies to enhance patient care.

Replica Analytics Ltd. is a Canadian company based in Ottawa that specializes in developing modeling software to create synthetic data derived from real clinical datasets. Founded in 2019, the company employs advanced machine learning technologies to generate privacy-protective synthetic data that retains the statistical properties of the original data. This platform not only facilitates the creation of high-utility synthetic datasets but also provides documentation regarding the utility characteristics of the data. By doing so, Replica Analytics enables businesses to access valuable data while adhering to global regulatory requirements for privacy protection and data analysis.

BioLib Technologies ApS is a Copenhagen-based company founded in 2019 that operates a biomedical data analysis platform focused on biological and health data. The company provides end-to-end bioinformatic data analytics, offering access to comprehensive datasets, analytic workflows, algorithms, and cloud-computing infrastructure. BioLib enables scientists and data holders to collaborate securely and efficiently, facilitating the analysis of genomic and healthcare data. By delivering a zero-knowledge analysis platform, BioLib accelerates the transition from raw experimental data to actionable insights, thereby supporting the development of new treatments and diagnostics and enhancing the pace of scientific discovery.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

PlenOptika, Inc. is a technology company based in Allston, Massachusetts, that specializes in the development of a handheld device called QuickSee, which provides accurate eyeglass prescriptions through precise refractive measurements. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology, the company addresses the significant global issue of low vision affecting over one billion people. QuickSee is designed to facilitate optometry, especially in rural and resource-limited settings, by simplifying the process of vision correction. The device captures the eye's full aberration fingerprint, effectively reducing the costs and physical space required by traditional autorefractors. PlenOptika aims to make eye care accessible to underserved communities worldwide and has received recognition from various social innovation foundations and business competitions for its contributions to healthcare technology.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, specializing in the development of a machine platform for the large-scale, industrial manufacturing of personalized cell therapies aimed at treating cancer. The company employs advanced semiconductor technology and microfluidic processing to facilitate real-time process control and manipulation at the cellular level. This innovative approach enables a fully automated and modular manufacturing system, enhancing the efficiency and safety of cell therapies while making them more cost-effective for patients. Based in Hinterstoder, Austria, Sarcura is poised to transform manufacturing paradigms in the field of patient-specific cancer treatment.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

contextflow develops AI-based solutions for radiology image search and analysis. Its flagship product is a 3D image-based search engine that delivers summary of clinical findings, similar reference cases, and relevant diagnosis support for radiologists. The company partners with healthcare institutions and pharmaceutical companies to enhance patient care.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

PlenOptika, Inc. is a technology company based in Allston, Massachusetts, that specializes in the development of a handheld device called QuickSee, which provides accurate eyeglass prescriptions through precise refractive measurements. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology, the company addresses the significant global issue of low vision affecting over one billion people. QuickSee is designed to facilitate optometry, especially in rural and resource-limited settings, by simplifying the process of vision correction. The device captures the eye's full aberration fingerprint, effectively reducing the costs and physical space required by traditional autorefractors. PlenOptika aims to make eye care accessible to underserved communities worldwide and has received recognition from various social innovation foundations and business competitions for its contributions to healthcare technology.

TeiaCare is a health technology company focused on enhancing the long-term care sector through the use of artificial intelligence. The company has developed ANCELIA, an advanced AI solution that automatically collects and analyzes data on the conditions of residents in care homes. This technology empowers healthcare workers and managers by improving daily assistance activities and allowing for the delivery of higher quality care to a greater number of residents without additional effort. By leveraging data, TeiaCare provides valuable insights and reports that optimize decision-making and management processes within nursing homes. The company emphasizes a new care model based on personalized assistance, objective data, and transparency, aiming to address inefficiencies in monitoring post-acute hospital patients and ensuring better outcomes for residents.

contextflow develops AI-based solutions for radiology image search and analysis. Its flagship product is a 3D image-based search engine that delivers summary of clinical findings, similar reference cases, and relevant diagnosis support for radiologists. The company partners with healthcare institutions and pharmaceutical companies to enhance patient care.

MindPeak GmbH is a technology company based in Hamburg, Germany, founded in 2018. It specializes in developing artificial intelligence software tools aimed at enhancing the accuracy and efficiency of cancer diagnostics. The company's flagship product, BreastAI, is designed for the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. MindPeak's solutions automate tissue diagnostics, enabling pathologists to identify and quantify tumorous regions and detect breast cancer cells more effectively. By streamlining tasks such as cell and biomarker quantification, MindPeak's tools allow cancer specialists to focus on critical decision-making in clinical environments, ultimately improving patient care while making diagnostic processes more accessible and cost-effective.

Kheiron Medical Technologies is a London-based medical technology company that develops Mia, an AI-powered mammography screening tool designed to help radiologists detect breast cancer. The system combines deep learning with radiology insights to improve detection efficiency, consistency, and accuracy across imaging workflows. Incorporated in 2016 and formerly known as Maesterai, the company maintains an international presence with offices in London, San Francisco, Budapest, and Amsterdam, aiming to advance precision radiology and improve outcomes for cancer patients.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.